ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the ...

AEMD CMO will present data on Hemopurifier potential in Long Covid at Keystone Symposium We met virtually with medical therapeutic company Aethlon Medical (NASDAQ:AEMD) this week and present our ...

today announced preclinical data will be presented at the inaugural AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research. The oral presentation, taking place on September 20 ...

CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma Patients GBM CTC isolation only possible with Parsortix label-free ...

Date/Time: ePoster will be made available on ECTRIMS platform beginning Wednesday, September 24 th and will remain available for 3 months after the congress ends Abstract Number/ePoster Number: ...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...

Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activityWhile clinical benefits were observed in all ...

LOS ANGELES, September 03, 2025--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces ...

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia ...

Researchers at Princeton University and the Simons Foundation have identified four clinically and biologically distinct subtypes of autism, marking a transformative step in understanding the condition ...